Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Parkinson Disease: HELP
Articles from New England
Based on 1,477 articles published since 2009
||||

These are the 1477 published articles about Parkinson Disease that originated from New England during 2009-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Subthalamic Nucleus and Globus Pallidus Internus Deep Brain Stimulation for the Treatment of Patients With Parkinson's Disease: Executive Summary. 2018

Rughani, Anand / Schwalb, Jason M / Sidiropoulos, Christos / Pilitsis, Julie / Ramirez-Zamora, Adolfo / Sweet, Jennifer A / Mittal, Sandeep / Espay, Alberto J / Martinez, Jorge Gonzalez / Abosch, Aviva / Eskandar, Emad / Gross, Robert / Alterman, Ron / Hamani, Clement. ·Neuroscience Institute, Maine Medical Center, Portland, Maine. · Department of Neurosurgery, Henry Ford Medical Gr-oup, West Bloomfield, Michigan. · De-partment of Neurology and Ophthal-mology, Michigan State University, Michigan. · Departments of Neuroscience and Experimental Therapeutics and of Neurosurgery, Albany Medical College, Albany, New York. · Center for Movement Disorders and Neurorestoration, Gain-esville, Florida. · Department of Neuro-surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio. · De-partment of Neurosurgery, Wayne State University, Detroit, Michigan. · James J. and Joan A. Gardner Center for Parkinson Disease and Movement Disorders, University of Cincinnati, Cincinnati, Ohio. · Neurological Institute, Cleveland Clinic, Cleveland, Ohio. · Department of Neurosurgery, University of Colorado School of Medicine, Aurora, Colorado. · Department of Neurological Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. · Department of Neu-rosurgery, Emory University, Atlanta, Georgia. · Division of Neurosurgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massa-chusetts. · Division of Neurosurgery, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. ·Neurosurgery · Pubmed #29538685.

ABSTRACT: QUESTION 1: Is bilateral subthalamic nucleus deep brain stimulation (STN DBS) more, less, or as effective as bilateral globus pallidus internus deep brain stimulation (GPi DBS) in treating motor symptoms of Parkinson's disease, as measured by improvements in Unified Parkinson's Disease Rating Scale, part III (UPDRS-III) scores? RECOMMENDATION: Given that bilateral STN DBS is at least as effective as bilateral GPi DBS in treating motor symptoms of Parkinson's disease (as measured by improvements in UPDRS-III scores), consideration can be given to the selection of either target in patients undergoing surgery to treat motor symptoms. (Level I). QUESTION 2: Is bilateral STN DBS more, less, or as effective as bilateral GPi DBS in allowing reduction of dopaminergic medication in Parkinson's disease? RECOMMENDATION: When the main goal of surgery is reduction of dopaminergic medications in a patient with Parkinson's disease, then bilateral STN DBS should be performed instead of GPi DBS. (Level I). QUESTION 3: Is bilateral STN DBS more, less, or as effective as bilateral GPi DBS in treating dyskinesias associated with Parkinson's disease? RECOMMENDATION: There is insufficient evidence to make a generalizable recommendation regarding the target selection for reduction of dyskinesias. However, when the reduction of medication is not anticipated and there is a goal to reduce the severity of "on" medication dyskinesias, the GPi should be targeted. (Level I). QUESTION 4: Is bilateral STN DBS more, less, or as effective as bilateral GPi DBS in improving quality of life measures in Parkinson's disease? RECOMMENDATION: When considering improvements in quality of life in a patient undergoing DBS for Parkinson's disease, there is no basis to recommend bilateral DBS in 1 target over the other. (Level I). QUESTION 5: Is bilateral STN DBS associated with greater, lesser, or a similar impact on neurocognitive function than bilateral GPi DBS in Parkinson disease? RECOMMENDATION: If there is significant concern about cognitive decline, particularly in regards to processing speed and working memory in a patient undergoing DBS, then the clinician should consider using GPi DBS rather than STN DBS, while taking into consideration other goals of surgery. (Level I). QUESTION 6: Is bilateral STN DBS associated with a higher, lower, or similar risk of mood disturbance than GPi DBS in Parkinson's disease? RECOMMENDATION: If there is significant concern about the risk of depression in a patient undergoing DBS, then the clinician should consider using pallidal rather than STN stimulation, while taking into consideration other goals of surgery. (Level I). QUESTION 7: Is bilateral STN DBS associated with a higher, lower, or similar risk of adverse events compared to GPi DBS in Parkinson's disease? RECOMMENDATION: There is insufficient evidence to recommend bilateral DBS in 1 target over the other in order to minimize the risk of surgical adverse events.  The full guideline can be found at: https://www.cns.org/guidelines/deep-brain-stimulation-parkinsons-disease.

2 Guideline Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. 2016

Coates, Laura C / Kavanaugh, Arthur / Mease, Philip J / Soriano, Enrique R / Laura Acosta-Felquer, Maria / Armstrong, April W / Bautista-Molano, Wilson / Boehncke, Wolf-Henning / Campbell, Willemina / Cauli, Alberto / Espinoza, Luis R / FitzGerald, Oliver / Gladman, Dafna D / Gottlieb, Alice / Helliwell, Philip S / Husni, M Elaine / Love, Thorvardur J / Lubrano, Ennio / McHugh, Neil / Nash, Peter / Ogdie, Alexis / Orbai, Ana-Maria / Parkinson, Andrew / O'Sullivan, Denis / Rosen, Cheryl F / Schwartzman, Sergio / Siegel, Evan L / Toloza, Sergio / Tuong, William / Ritchlin, Christopher T. ·Leeds Institute of Rheumatic and Musculoskeletal Medicine and University of Leeds, Leeds, UK. · University of California at San Diego. · Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington. · Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. · University of Southern California, Keck School of Medicine, Los Angeles. · Hospital Militar Central and Universidad Militar Nueva Grenada, Bogotá, Colombia. · Geneva University Hospital, Geneva, Switzerland. · Toronto Western Hospital, Toronto, Ontario, Canada. · University of Cagliari, Monserrato Campus, Cagliari, Italy. · Louisiana State University Health Sciences Center, New Orleans. · St. Vincent's University Hospital, The Conway Institute for Biomolecular Research, and University College Dublin, Dublin, Ireland. · University of Toronto and Toronto Western Research Institute, Toronto, Ontario, Canada. · Tufts Medical Center, Boston, Massachusetts. · Leeds Institute of Rheumatic and Musculoskeletal Medicine and University of Leeds, Leeds, UK, and Bradford Hospitals NHS Foundation Trust, Bradford, UK. · Cleveland Clinic Foundation, Cleveland, Ohio. · University of Iceland and Landspitali University Hospital, Reykjavik, Iceland. · University of Molise, Campobasso, Italy. · Royal National Hospital for Rheumatic Diseases, Bath, UK. · University of Queensland, Brisbane, Queensland, Australia. · University of Pennsylvania, Philadelphia. · Johns Hopkins University School of Medicine, Baltimore, Maryland. · Chapel Allerton Hospital, Leeds, UK. · St. Vincent's University Hospital, Dublin, Ireland. · Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada. · Hospital for Special Surgery, New York, New York. · Arthritis and Rheumatism Associates, Rockville, Maryland. · Ministry of Health, San Fernando del Valle de Catamarca, Argentina. · University of California, Davis. · University of Rochester Medical Center, Rochester, New York. ·Arthritis Rheumatol · Pubmed #26749174.

ABSTRACT: OBJECTIVE: To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting patients with psoriatic arthritis (PsA). METHODS: GRAPPA rheumatologists, dermatologists, and PsA patients drafted overarching principles for the management of PsA, based on consensus achieved at face-to-face meetings and via online surveys. We conducted literature reviews regarding treatment for the key domains of PsA (arthritis, spondylitis, enthesitis, dactylitis, skin disease, and nail disease) and convened a new group to identify pertinent comorbidities and their effect on treatment. Finally, we drafted treatment recommendations for each of the clinical manifestations and assessed the level of agreement for the overarching principles and treatment recommendations among GRAPPA members, using an online questionnaire. RESULTS: Six overarching principles had ≥80% agreement among both health care professionals (n = 135) and patient research partners (n = 10). We developed treatment recommendations and a schema incorporating these principles for arthritis, spondylitis, enthesitis, dactylitis, skin disease, nail disease, and comorbidities in the setting of PsA, using the Grading of Recommendations, Assessment, Development and Evaluation process. Agreement of >80% was reached for approval of the individual recommendations and the overall schema. CONCLUSION: We present overarching principles and updated treatment recommendations for the key manifestations of PsA, including related comorbidities, based on a literature review and consensus of GRAPPA members (rheumatologists, dermatologists, other health care providers, and patient research partners). Further updates are anticipated as the therapeutic landscape in PsA evolves.

3 Guideline Recommendations of the Alzheimer's disease-related dementias conference. 2014

Montine, Thomas J / Koroshetz, Walter J / Babcock, Debra / Dickson, Dennis W / Galpern, Wendy R / Glymour, M Maria / Greenberg, Steven M / Hutton, Michael L / Knopman, David S / Kuzmichev, Andrey N / Manly, Jennifer J / Marder, Karen S / Miller, Bruce L / Phelps, Creighton H / Seeley, William W / Sieber, Beth-Anne / Silverberg, Nina B / Sutherland, Margaret / Torborg, Christine L / Waddy, Salina P / Zlokovic, Berislav V / Corriveau, Roderick A / Anonymous800802. ·From the Department of Pathology (T.J.M.), University of Washington, Seattle · National Institute of Neurological Disorders and Stroke (W.J.K., D.B., W.R.G., A.N.K., B.-A.S., M.S., C.L.T., S.P.W., R.A.C.), Bethesda, MD · Neuropathology Lab (D.W.D.), Mayo Clinic, Jacksonville, FL · Department of Epidemiology & Biostatistics (M.M.G.), University of California San Francisco · Hemorrhagic Stroke Research Program (S.M.G.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA · Neurodegenerative Diseases DHT at Eli Lilly and Company (M.L.H.), Lilly Research Center, Windlesham, UK · Department of Neurology (D.S.K.), Mayo Clinic Rochester, MN · Taub Institute for Research on Alzheimer's Disease and the Aging Brain (J.J.M., K.S.M.), Columbia University Medical Center, New York · Columbia University (J.J.M., K.S.M.), College of Physicians and Surgeons, New York, NY · University of California San Francisco Memory and Aging Center (B.L.M., W.W.S.) · National Institute on Aging (C.H.P., N.B.S.), Bethesda, MD · and Zilhka Neurogenetic Institute (B.V.Z.), Center for Neurodegeneration and Regeneration and Department of Physiology and Biophysics, University of Southern California, Keck School of Medicine, Los Angeles, CA. ·Neurology · Pubmed #25080517.

ABSTRACT: The National Alzheimer's Project Act, signed into law in 2011, mandates a National Plan to Address Alzheimer's Disease that is updated annually. In the Plan, the term Alzheimer disease includes not only Alzheimer disease (AD) proper, but also several specified related dementias, namely, frontotemporal, Lewy body, vascular, and mixed dementia. In response to a specific action item in the 2012 National Plan, the National Institute of Neurological Disorders and Stroke, in collaboration with the National Institute on Aging, convened panels of experts and conducted a 2-day public conference to develop research priorities and timelines for addressing Alzheimer disease-related dementias (ADRD) in 5 topic areas: multiple etiology dementias, health disparities, Lewy body dementias including dementia with Lewy bodies and Parkinson disease dementia, frontotemporal dementia and related tauopathies, and vascular contributions to ADRD. By design, the product was up to 8 prioritized research recommendations in each topic area including estimated timelines from when work on a recommendation is started to completion or to full implementation of an ongoing activity, and recognition of shared research themes across recommendations. These included increased education and training of both researchers and health care professionals, addressing health disparities, fundamental neurobiology research, advanced diagnostics, collaborative biosample repositories, and a focus on developing effective interventions to prevent or treat ADRD by the year 2025 as targeted by the National Plan.

4 Editorial Editorial to "Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: retrospective cohort study" by Friedman et al. 2019

Friedman, Joseph H / Violante, Mayela Rodriguez / Miyasaki, Janis M. ·Department of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, USA. Electronic address: Joseph_friedman@brown.edu. · Laboratorio Clinico de Enfermedades Neurodegenerativas, Instituo Nacional de Neuroligia y Neurocirugia, Mexico. Electronic address: mrodriguez@innn.edu.mx. · Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. Electronic address: miyasaki@ualberta.ca. ·Parkinsonism Relat Disord · Pubmed #31759870.

ABSTRACT: -- No abstract --

5 Editorial Commentary on "The Neuropsychiatry of Parkinson's Disease: A Perfect Storm". 2019

Friedman, Joseph H. ·Movement Disorders Program, Butler Hospital; Division of Movement Disorders, Department of Neurology, Warren Alpert Medical School, Brown University; and School of Pharmacy, University of Rhode Island. Electronic address: joseph_friedman@brown.edu. ·Am J Geriatr Psychiatry · Pubmed #30987802.

ABSTRACT: -- No abstract --

6 Editorial Introduction to special issue on Advances in Brain Imaging. 2019

Morris, Evan D. ·Department of Radiology and Biomedical Imaging, Yale University, New Haven, CT, USA. evan.morris@yale.edu. · Department of Biomedical Engineering, Yale University, New Haven, CT, USA. evan.morris@yale.edu. · Department of Psychiatry, Yale University, New Haven, CT, USA. evan.morris@yale.edu. ·Brain Imaging Behav · Pubmed #30825119.

ABSTRACT: -- No abstract --

7 Editorial Deep brain stimulation for Parkinson's disease - Does measuring quality matter? 2019

Ba, Fang / Jimenez-Shahed, Joohi. ·Division of Neurology, Department of Medicine, University of Alberta, 7-131 Clinical Sciences Building, 11350, 83 Avenue, Edmonton, Alberta, T6G 2G3, Canada. Electronic address: fb@ualberta.ca. · Baylor College of Medicine, 7200 Cambridge St., 9th floor, Houston, TX, 77030, USA. Electronic address: jshahed@bcm.edu. ·Parkinsonism Relat Disord · Pubmed #30796008.

ABSTRACT: -- No abstract --

8 Editorial Enlightened PD: A novel treatment for Parkinson disease? 2019

Videnovic, Aleksandar / Messinis, Lambros. ·From the Department of Neurology (A.V.), Massachusetts General Hospital, Harvard Medical School, Boston · and Neuropsychology Section (L.M.), Departments of Psychiatry and Neurology, University Hospital of Patras, University of Patras Medical School, Rio, Greece. ·Neurology · Pubmed #30770427.

ABSTRACT: -- No abstract --

9 Editorial Enabling biomarker discovery in Parkinson's disease using multiomics: challenges, promise and the future. 2019

Kiebish, Michael A / Narain, Niven R. ·BERG LLC, Precision Medicine Division, Framingham, MA 01701, USA. ·Per Med · Pubmed #30422077.

ABSTRACT: -- No abstract --

10 Editorial Life expectancy in Parkinson disease. 2018

Golbe, Lawrence I / Leyton, Cristian E. ·From the Department of Neurology (L.I.G.), Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ · Department of Neurology (C.E.L.), Frontotemporal Disorders Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA · and Faculty of Health Sciences (C.E.L.), Brain and Mind Centre, The University of Sydney, Australia. ·Neurology · Pubmed #30381371.

ABSTRACT: -- No abstract --

11 Editorial Perspective on Pimavanserin and the SAPS-PD: Novel Scale Development as a Means to FDA Approval. 2018

Schubmehl, Sarah / Sussman, Joleen. ·VA Maine Healthcare System, Augusta, ME. Electronic address: Sarah.Schubmehl@gmail.com. · VA Eastern Colorado Health Care System, Denver, CO. ·Am J Geriatr Psychiatry · Pubmed #30072306.

ABSTRACT: In 2016, pimavanserin, a 5-hydroxytryptamine 2A inverse agonist, became the first U.S. Food and Drug Administration (FDA) approved medication for Parkinson disease psychosis (PDP) after demonstrating modest clinical improvement in a single positive trial as assessed by a novel PDP scale, the Scale for the Assessment of Positive Symptoms for Parkinson's Disease Psychosis (SAPS-PD). This followed three trials that demonstrated negative findings on established measures of psychosis widely used in PDP research, including the Brief Psychiatric Rating Scale, the Scale for the Assessment of Positive Symptoms, the Parkinson Psychosis Rating Scale, and the Clinical Global Impression-Severity Scale. This review article provides an overview of the scale construction of the SAPS-PD, a measure which has yet to be established as valid, reliable, or sensitive to change in PDP. Furthermore, this article reviews analyses completed by an FDA statistical reviewer that call into question whether pimavanserin demonstrated a clinically significant difference from placebo on the SAPS-PD. These findings underscore concerns regarding the clinical efficacy of pimavanserin.

12 Editorial Discovering New Benefits From Old Drugs With Big Data-Promise for Parkinson Disease. 2018

Olsen, Abby L / Riise, Trond / Scherzer, Clemens R. ·Precision Neurology Program, Brigham and Women's Hospital, Boston, Massachusetts. · Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts. · Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts. · Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. · Neurogenomics Laboratory, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts. · Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts. ·JAMA Neurol · Pubmed #29710184.

ABSTRACT: -- No abstract --

13 Editorial Neurotherapeutics: Recent Developments. 2018

Rizvi, Syed. ·Associate Professor of Clinical Neurosciences, Alpert Medical School of Brown University; Director, Rhode Island Hospital Multiple Sclerosis Center; Director, Neurology Outpatient Center. ·R I Med J (2013) · Pubmed #29490320.

ABSTRACT: -- No abstract --

14 Editorial MCI in Parkinson's disease. 2018

Friedman, Joseph H. ·Dept. of Neurology, Butler Hospital, 345 Blackstone Blvd, Providence, RI 02906, USA; Dept. of Neurology, Warren Alpert Medical School of Brown University, Providence, RI 02906, USA. Electronic address: Joseph_friedman@brown.edu. ·Parkinsonism Relat Disord · Pubmed #29413123.

ABSTRACT: -- No abstract --

15 Editorial Immunologic treatment of Parkinson's disease. 2018

Jankovic, Joseph. ·Distinguished Chair in Movement Disorders, Director, Parkinson's Disease Center & Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 7200 Cambridge, Suite 9A; Houston, TX 77030-4202, USA. ·Immunotherapy · Pubmed #29260621.

ABSTRACT: -- No abstract --

16 Editorial Dietary antioxidants and Parkinson's disease. 2017

Ascherio, Alberto / Schwarzschild, Michael A. ·Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. · Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA. · Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. · Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA. ·Mov Disord · Pubmed #28976040.

ABSTRACT: -- No abstract --

17 Editorial Editorial and introduction: Behavioral aspects of Parkinson's disease. 2017

Friedman, Joseph H / Bhidayasiri, Roongroj / Truong, Daniel D. ·Butler Hospital, Department of Neurology, Alpert Medical School of Brown University, RI, USA. · Chulalongkorn Center of Excellence for Parkinson's Disease & Related Disorders, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok 10330, Thailand; Department of Rehabilitation Medicine, Juntendo University, Tokyo, Japan. Electronic address: rbh@chulapd.org. · Truong Neuroscience Institute, Parkinson's and Movement Disorders Institute, Orange Coast Memorial Medical Center, Fountain Valley, CA, USA. ·J Neurol Sci · Pubmed #28087061.

ABSTRACT: -- No abstract --

18 Editorial Understanding of the role of manganese in parkinsonism and Parkinson disease. 2017

Ratner, Marcia H / Fitzgerald, Edward. ·From the Laboratory of Molecular Neurobiology (M.H.R.), Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, MA · and Department of Environmental Health Sciences (E.F.), School of Public Health, University at Albany, Rensselaer, NY. ·Neurology · Pubmed #28031391.

ABSTRACT: -- No abstract --

19 Editorial Thoughts on fatigue in Parkinson's disease (and other disorders). 2017

Friedman, J H. ·Butler Hospital, Providence, RI, USA. · Department of Neurology, Warren Alpert Medical School of Brown University, Providence, RI, USA. ·Eur J Neurol · Pubmed #27699949.

ABSTRACT: -- No abstract --

20 Editorial Advances in sensor and wearable technologies for Parkinson's disease. 2016

Sánchez-Ferro, Álvaro / Maetzler, Walter. ·HM CINAC, Hospital Universitario HM Puerta del Sur, Móstoles, Madrid, Spain. · Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. · Center for Neurology and Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, University of Tübingen, Tübingen, Germany. walter.maetzler@uni-tuebingen.de. · German Center for Neurodegenerative Diseases, Tübingen, Germany. walter.maetzler@uni-tuebingen.de. ·Mov Disord · Pubmed #27477675.

ABSTRACT: -- No abstract --

21 Editorial 4-amino-7-chloroquinoline derivatives for treating Parkinson's disease: implications for drug discovery. 2016

Kim, Chun-Hyung / Leblanc, Pierre / Kim, Kwang-Soo. ·a Molecular Neurobiology Laboratory , McLean Hospital and Program in Neuroscience, Harvard Medical School , Belmont , MA , USA. · b Paean Biotechnology Inc. , Daejeon , Korea. ·Expert Opin Drug Discov · Pubmed #26924734.

ABSTRACT: -- No abstract --

22 Editorial Editorial overview: Neurobiology of disease. 2016

Selkoe, Dennis J / Weinberger, Daniel R. ·Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: dselkoe@partners.org. · Lieber Institute for Brain Development and Johns Hopkins School of Medicine, Baltimore, MD, USA. Electronic address: drweinberger@libd.org. ·Curr Opin Neurobiol · Pubmed #26797413.

ABSTRACT: -- No abstract --

23 Editorial Editorial on: Pagonabarraga J, Martinez-Hora S, Fernandez de Bobadilla R et al. Minor hallucinations occur in drug-naïve Parkinson's disease patients even from the premotor phase. Movement Disorders 2015; Available from: DOI: 10.1002/mds.26432. 2016

Friedman, Joseph H. ·Movement Disorders Program, Butler Hospital, Providence, RI. · Department of Neurology, Warren Alpert School of Medicine of Brown University, Providence, RI. ·Mov Disord · Pubmed #26660462.

ABSTRACT: -- No abstract --

24 Editorial Hope for regenerative treatments: toward safe transplantation of human pluripotent stem-cell-based therapies. 2015

Kimbrel, Erin A / Lanza, Robert. ·Ocata Therapeutics (formerly Advanced Cell Technology), Marlborough, MA 01752, USA. ·Regen Med · Pubmed #25835474.

ABSTRACT: -- No abstract --

25 Editorial Smoking and osteoarthritis: a review of the evidence and its implications. 2015

Felson, D T / Zhang, Y. ·Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, USA; NIHR Biomedical Research Unit, University of Manchester, Manchester, UK. Electronic address: dfelson@bu.edu. · Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, USA. ·Osteoarthritis Cartilage · Pubmed #25454371.

ABSTRACT: A number of reports including a recent publication in Osteoarthritis and Cartilage have suggested that smokers have a lower than expected prevalence of osteoarthritis (OA) than nonsmokers. We review the evidence linking smoking with OA, suggest approaches whereby the direct and indirect effects of smoking on OA might be distinguished, highlight two diseases, ulcerative colitis and Parkinson's disease, where smoking is protective, discuss mechanisms by which nicotine might act and lastly explore the association of smoking with enhanced musculoskeletal pain.

Next